Rani Therapeutics Holdings, Inc. (RANI): Cash & Equivalents
$18.62M
As of 2025-12-31
$4.87M
As of 2026-06-30
-11.7%
3-year compound annual growth
-23.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.62M | +394.9% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $3.76M | -35.8% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $5.86M | -78.3% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $27.01M | -77.0% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $117.45M | +60.8% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $73.06M | n/a | 2022-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $18.62M | +394.9% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $7.80M | +440.3% |
| Bio Essence Corp (BIOE) | 2024-12-31 | $1.4K | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.85M | +10.1% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $3.04M | +39.8% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.8K | -16.3% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $5.21M | -16.1% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $51.09M | +124.1% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $3.24M | +0.2% |
Compare RANI, NRXP, BIOE, ATXI side by side · Screen every company in Pharmaceutical Preparations ↗